Amylyx Pharmaceuticals, Inc. 8-K

What Happened
Amylyx Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release dated May 7, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K filed with the SEC on May 7, 2026. The Form 8-K notes that the furnished materials are not “filed” under Section 18 of the Exchange Act and are not incorporated by reference into other SEC filings unless expressly stated.

Key Details

• Press release announcing quarterly results dated and furnished on May 7, 2026 (Exhibit 99.1).
• Financial period covered: quarter ended March 31, 2026 (Q1 2026).
• The 8-K was signed by James M. Frates, Chief Financial Officer, on May 7, 2026.
• The filing clarifies the press release is furnished (not filed) and therefore not subject to Section 18 liability or automatic incorporation by reference.

Why It Matters
Investors should review the May 7, 2026 press release (Exhibit 99.1) to see the company’s reported revenue, earnings or losses, and any commentary on guidance or business trends for Q1 2026. Because the release is furnished rather than filed, statements in it are not automatically treated as incorporated into other SEC filings—so investors seeking durable disclosure should also watch for subsequent filed reports (e.g., Form 10-Q) or investor presentations for formal, filed financial statements and additional detail.